Mutual of America Capital Management LLC Reduces Holdings in Kenvue Inc. $KVUE

Mutual of America Capital Management LLC decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 25.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 219,849 shares of the company's stock after selling 73,973 shares during the quarter. Mutual of America Capital Management LLC's holdings in Kenvue were worth $4,601,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC grew its stake in Kenvue by 33.2% during the 1st quarter. GAMMA Investing LLC now owns 24,778 shares of the company's stock valued at $594,000 after acquiring an additional 6,169 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its position in shares of Kenvue by 4.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock valued at $2,545,000 after purchasing an additional 4,034 shares in the last quarter. Continuum Advisory LLC grew its position in shares of Kenvue by 2,071.1% in the first quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock valued at $47,000 after purchasing an additional 1,864 shares in the last quarter. Oppenheimer & Co. Inc. grew its position in shares of Kenvue by 5.3% in the first quarter. Oppenheimer & Co. Inc. now owns 172,255 shares of the company's stock valued at $4,131,000 after purchasing an additional 8,693 shares in the last quarter. Finally, Asset Management One Co. Ltd. grew its position in shares of Kenvue by 6.9% in the first quarter. Asset Management One Co. Ltd. now owns 801,376 shares of the company's stock valued at $19,217,000 after purchasing an additional 51,796 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Stock Performance

NYSE:KVUE opened at $15.20 on Thursday. Kenvue Inc. has a fifty-two week low of $14.05 and a fifty-two week high of $25.17. The company has a 50 day moving average price of $18.15 and a 200 day moving average price of $20.89. The stock has a market capitalization of $29.16 billion, a P/E ratio of 20.53, a PEG ratio of 2.15 and a beta of 0.72. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The business had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same period last year, the business posted $0.32 earnings per share. The company's quarterly revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were paid a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a dividend yield of 5.5%. Kenvue's payout ratio is 112.16%.

Analysts Set New Price Targets

KVUE has been the subject of several analyst reports. UBS Group dropped their target price on Kenvue from $23.00 to $17.00 and set a "neutral" rating for the company in a report on Wednesday, October 8th. Weiss Ratings reissued a "hold (c-)" rating on shares of Kenvue in a report on Tuesday, October 14th. Redburn Partners set a $22.00 price objective on shares of Kenvue in a report on Friday, September 26th. Canaccord Genuity Group dropped their price target on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Finally, Evercore ISI dropped their price target on shares of Kenvue from $23.00 to $18.00 and set an "in-line" rating for the company in a research note on Tuesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Kenvue presently has a consensus rating of "Hold" and an average price target of $21.18.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.